Cannabidivarin - GW Pharmaceuticals

Drug Profile

Cannabidivarin - GW Pharmaceuticals

Alternative Names: CBDV - GW Pharmaceuticals; GWP-42006

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator GW Pharmaceuticals
  • Developer Charite of Berlin; GW Pharmaceuticals
  • Class Antiepileptic drugs; Cannabinoids; Small molecules
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rett syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuropathic pain; Partial epilepsies
  • Phase I Epilepsy; Pervasive child development disorders

Most Recent Events

  • 19 Jan 2017 Phase-I clinical trials in Pervasive child development disorders (unspecified route) (GW Pharmaceuticals pipeline, January 2017)
  • 30 Nov 2016 GW Pharmaceuticals' Cannabidivarin receives Orphan Drug status for Rett syndrome in USA
  • 05 May 2016 Preclinical trials in Pervasive child development disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top